Last reviewed · How we verify
caspofungin antifungal therapy
Caspofungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls.
Caspofungin inhibits the synthesis of beta-1,3-D-glucan, an essential component of fungal cell walls. Used for Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis.
At a glance
| Generic name | caspofungin antifungal therapy |
|---|---|
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Drug class | Echinocandin antifungal |
| Target | Beta-1,3-D-glucan synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This leads to cell lysis and ultimately cell death. Caspofungin is a member of the echinocandin class of antifungal agents.
Approved indications
- Treatment of invasive aspergillosis, invasive candidiasis, and esophageal candidiasis
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
- Headache
- Fatigue
- Pyrexia
- Hypokalemia
- Hypomagnesemia
- Elevated liver enzymes
Key clinical trials
- Pharmacokinetics of Caspofungin in Burn Patients (PHASE2, PHASE3)
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study) (PHASE4)
- A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
- CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia (PHASE1, PHASE2)
- Study Comparing Caspofungin to Placebo for the Treatment of ICU Intra-abdominal Candidiasis (PHASE3)
- Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
- Empirical Versus Preemptive Antifungal Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: